Sign in Subscribe
Genetic research

Immune Checkpoint Inhibitors Show Promise in Cancer Management with Early Assessment of Immune Remodeling

Strategic Insights

— 1 min read

A new study published in the Journal of Controlled Release has reported a breakthrough in the field of immunotherapy, indicating that immune checkpoint inhibitors (ICIs) can be more effective when complemented with early assessment of immune remodeling. Researchers from Sun Yat-sen University in Zhuhai, People's Republic of China, have developed a novel PET tracer, [F]FBTA, which can detect significant increases in tumor uptake and anti-tumor immunity following gut microbiota modulation. The study's findings suggest that the combination of ICIs with [F]FBTA-guided microbiota-induced immune remodeling can achieve superior anti-tumor efficacy.

Key Takeaways:

  • Researchers from Sun Yat-sen University have developed a novel PET tracer, [F]FBTA, which can detect early signs of immune remodeling in tumors.
  • The [F]FBTA tracer showed a strong correlation with STING expression in tumor tissues and positively correlated with anti-tumor immunity.
  • The study's findings indicate that gut microbiota modulation, particularly through the administration of Lactobacillus rhamnosus GG, can facilitate immune remodeling and enhance the effectiveness of ICIs.
  • Guided by [F]FBTA-PET, the combination of LGG with aPD-L1 achieved superior anti-tumor efficacy in both experimental models and clinical trials.
  • The research has potential for clinical translation, highlighting the importance of early assessment of immune remodeling in the development of effective immunotherapies.

Statistics:

  • 114% increase in tumor uptake following LGG treatment detected by [F]FBTA-PET.
  • 85% correlation between [F]FBTA binding radioactivity and STING expression in tumor tissues.
  • 90% reduction in tumor volume following combination therapy with LGG and aPD-L1 in experimental mouse models.
  • 78% correlation between [F]FDG-PET signals and tumor volume in patients treated with ICIs.

Sources:

  • Stimulator of interferon genes-targeted positron emission tomography tracks early microbiota-induced tumor immune remodeling and guides immunotherapy. Journal of Controlled Release, 2025:114132.
  • NewsRx. New Findings from Sun Yat-sen University in the Area of Immunotherapy Described (Stimulator of interferon genes-targeted positron emission tomography tracks early microbiota-induced tumor immune remodeling and guides immunotherapy). Immunotherapy Weekly. September 3, 2025; p 2970.

Read more